학술논문
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Document Type
Article
Author
Source
Subject
*BREAST cancer
*HORMONE receptor positive breast cancer
*MEDICAL societies
*
*
Language
ISSN
0923-7534